Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplet Chemotherapy in Resectable Colorectal Cancer
NCT02688023Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Mar 2014
- Primary completion
- Dec 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, tegafur and capecitabine in colorectal cancer (CRC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: 3-year Disease-Free Survival. Status: unknown.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouraciltegafurcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02688023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688023.